The global pharmaceutical contract manufacturing market is projected to grow from USD 209.90 billion in 2025 to USD 311.95 billion by 2030, at a CAGR of 8.2%. Growth looks steady, but the drivers are quite specific. Capacity shortages in GLP-1 production, rising ADC pipelines, patent expiries, and demand for biosimilars are all pushing more work toward CDMOs.
Key takeaways
North America held a 40.3% share of the peptide synthesis market in 2024. Drug development services are set to grow fastest, with a CAGR of 12.2%. Large molecules will lead molecule growth, while big pharmaceutical companies remain the dominant end users, growing at 8.7%.
Companies such as Thermo Fisher Scientific, Lonza, and Catalent continue to hold strong positions due to scale and service breadth.
Market dynamics
Driver, GLP-1 capacity constraints
Demand for GLP-1 drugs is outpacing manufacturing capacity. In-house capabilities are limited, and scale-up takes time. This pushes pharmaceutical companies toward CDMOs for GMP production and faster commercialization.
Restraint, pricing pressure on innovator drugs
Pricing pressure from payers and regulators is tightening margins. Companies are turning to outsourcing to control costs, improve efficiency, and maintain profitability across high-value portfolios.
Opportunity, cell and gene therapies
Cell and gene therapies require specialized facilities, viral vector production, and strict compliance standards. CDMOs are expanding into these areas, which opens long-term partnerships and higher-margin services.
Challenge, trade instability and insourcing
Supply chains remain exposed to tariffs, geopolitical shifts, and regulatory barriers. At the same time, some pharma companies are reconsidering partial insourcing. This creates a mixed environment where CDMOs must stay flexible and regionally diversified.
Segment insights
By service
Manufacturing services hold the largest share and will likely continue to do so. The reason is simple, commercial-scale production of APIs, biologics, and injectables requires heavy infrastructure and long-term contracts, which generate consistent revenue.
By molecule
Large molecules dominate and are growing fastest. Biologics, monoclonal antibodies, and advanced therapies require complex manufacturing setups, which are often outsourced due to cost and expertise barriers.
By end user
Big pharmaceutical companies lead this segment. Their reliance on outsourcing is tied to large-scale production needs, biologics expansion, and supply chain optimization.
Regional outlook
Asia Pacific is expected to grow the fastest. China, India, South Korea, and Singapore are investing heavily in GMP infrastructure, automation, and biologics manufacturing. Lower costs and increasing technical capabilities make the region a preferred outsourcing destination. You might think cost is the only factor, but capacity expansion and regulatory improvements are playing an equally important role.
Competitive landscape
Key players include WuXi AppTec, WuXi Biologics, Samsung Biologics, Boehringer Ingelheim, Evonik Industries, FUJIFILM Corporation, AbbVie, Merck KGaA, and Charles River Laboratories.
What stands out is how these companies are expanding into high-value areas like biologics, viral vectors, and fill-finish services. At first glance, it looks like a capacity race. But it’s also about specialization. Not every CDMO can handle advanced therapies, and that gap is shaping competition.
